Skip to main content

Gene Security Network Raises $20M, Renames Itself Natera

NEW YORK (GenomeWeb News) – Gene Security Network today announced it has completed a $20 million financing round and changed its name to Natera.

The funds will go toward development and commercialization of the company's non-invasive prenatal diagnostic test for Down syndrome and other genetic ailments. A clinical trial funded by the National Institutes of Health for the prenatal test also will be expanded with a launch of the test anticipated sometime this year.

Its test uses bioinformatics technology to deliver results from quantities of DNA as small as that from a single cell, it said.

Lightspeed Venture Partners led the round and were joined by existing investors Claremont Creek Ventures and Sequoia Capital.

Natera, based in Redwood City, Calif., raised $4 million in a Series A round in 2007 and $6 million and $12 million in subsequent rounds.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.